Detalhe da pesquisa
1.
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.
Immunity
; 55(3): 512-526.e9, 2022 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263569
2.
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 627(8004): 646-655, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418879
3.
Peripheral T cell expansion predicts tumour infiltration and clinical response.
Nature
; 579(7798): 274-278, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32103181
4.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 627(8005): E11, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480897
5.
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Nature
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38816613
6.
CD96 functions as a co-stimulatory receptor to enhance CD8+ T cell activation and effector responses.
Eur J Immunol
; 50(6): 891-902, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043568
7.
B cell lymphoma 2 (Bcl-2) residues essential for Bcl-2's apoptosis-inducing interaction with Nur77/Nor-1 orphan steroid receptors.
J Biol Chem
; 293(13): 4724-4734, 2018 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29414782